Traders Purchase Large Volume of Call Options on DaVita (NYSE:DVA)

DaVita Inc. (NYSE:DVA) was the recipient of some unusual options trading activity on Friday. Investors acquired 6,418 call options on the company. This is an increase of approximately 884% compared to the typical daily volume of 652 call options.

Hedge Funds Weigh In On DaVita

Institutional investors have recently bought and sold shares of the business. Edgestream Partners L.P. bought a new position in shares of DaVita during the second quarter worth approximately $6,375,000. Dynamic Technology Lab Private Ltd acquired a new stake in DaVita during the first quarter worth approximately $364,000. Norges Bank bought a new position in DaVita during the 2nd quarter worth $32,986,000. Arrowstreet Capital Limited Partnership increased its stake in DaVita by 132.1% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 264,084 shares of the company’s stock worth $37,619,000 after acquiring an additional 150,318 shares during the period. Finally, Caxton Associates LLP bought a new stake in shares of DaVita during the 1st quarter valued at $513,000. Institutional investors and hedge funds own 90.12% of the company’s stock.

DaVita Stock Performance

DVA traded down $0.21 during trading on Friday, reaching $115.94. 149,804 shares of the stock were exchanged, compared to its average volume of 857,376. The stock’s 50 day moving average price is $121.55 and its two-hundred day moving average price is $131.61. DaVita has a twelve month low of $113.97 and a twelve month high of $179.60. The stock has a market cap of $8.19 billion, a P/E ratio of 11.93, a price-to-earnings-growth ratio of 0.89 and a beta of 1.00.

DaVita (NYSE:DVA) last announced its quarterly earnings data on Wednesday, October 29th. The company reported $2.51 EPS for the quarter, missing analysts’ consensus estimates of $3.17 by ($0.66). The firm had revenue of $3.42 billion during the quarter, compared to the consensus estimate of $3.43 billion. DaVita had a net margin of 5.80% and a negative return on equity of 13,370.89%. The business’s revenue was up 4.8% on a year-over-year basis. During the same period last year, the business earned $2.59 EPS. DaVita has set its FY 2025 guidance at 10.350-11.150 EPS. Equities research analysts predict that DaVita will post 10.76 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on DVA shares. Truist Financial set a $140.00 price objective on shares of DaVita in a report on Tuesday, October 14th. UBS Group reiterated a “buy” rating on shares of DaVita in a report on Monday. TD Cowen cut their price target on DaVita from $154.00 to $133.00 and set a “hold” rating on the stock in a report on Monday, November 3rd. Bank of America decreased their price objective on DaVita from $145.00 to $140.00 and set an “underperform” rating for the company in a report on Wednesday, September 10th. Finally, Cowen reissued a “hold” rating on shares of DaVita in a research report on Monday, November 3rd. One investment analyst has rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $148.00.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.